Tumors of the pancreas: Difference between revisions
Feedback

From WikiLectures

No edit summary
Line 79: Line 79:
</noinclude>
</noinclude>


[[Category:Chirurgy]]
[[Category:Surgery]]
[[Category:Oncology]]
[[Category:Oncology]]

Revision as of 19:06, 7 April 2022

Under construction / Forgotten

This article was marked by its author as Under construction, but the last edit is older than 30 days. If you want to edit this page, please try to contact its author first (you fill find him in the history). Watch the discussion as well. If the author will not continue in work, remove the template {{Under construction}} and edit the page.

Last update: Thursday, 07 Apr 2022 at 7.06 pm.

  • benign tumors occur very rarely
    • lipoma, cystadenomas, dermoid cysts, teratomas , apudomas
    • cystadenomas tend to malignate, they are removed
  • malignant tumors – we distinguish ampular tumors and then pancreatic cancer

Regional pancreatic lymph nodes

  • upper group - overhead and body
  • lower group - under the head and body
  • anterior group - pancreatoduodenal, pyloric and proximal mesenteric nodes
  • posterior group - posterior pancreatoduodenal, pericholedochal, mesenteric
  • lienal group - nodules in the hilus of the spleen

Ampullar (periampullar) tumors

  • most often it is a well-differentiated adenocarcinoma with papillary exophytic manifestations
  • used to be a rare rarity, today it is the fifth most common cause of cancer death
  • affects people over 50 years of age
  • prognostically favorable is that it soon manifests as obstructive jaundice - therefore it is indicated up to 4 times more *often for resection than pancreatic head cancer
  • metastases occur later

Carcinoma

Searchtool right.svg For more information see Pancreatic carcinoma.
Pancreatic head carcinoma after contrast application of CT
  • according to the location we recognize - carcinoma of the head, body and cauda pancreas
  • occurrence
    • is increasingly common (currently about 2 times more than in the interwar period)
    • make up over 10% of GIT malignancies, over 3% of all malignancies
  • causes - a number of predisposing factors are known - obesity , alcohol, smoking , DM , biliopancreatic reflux, chronic pancreatitis
  • localization - 65-70% is in the head, 15% in the body, 5% in the cauda area
  • histology - 90% are adenocarcinomas of the ductal epithelium, acinar cell carcinoma has a very poor prognosis

stages of the tumor process

  • stage I - T1 or 2, N0, M0
  • stage II - T3 (infiltration into the stomach, blood vessels), N0, M0
  • stage III - any T, N1, M0
  • stage IV - any T, N, but M1

Clinical picture

  • initially presents as:
    • "discomfort" syndrome - anorexia, fullness, weight loss and indigestion
    • these symptoms should lead to the suspicion of pancreatic malignancy
  • pain - in the abdomen and banded in the back
  • in head tumor - obstructive jaundice - typical painless onset

Diagnosis

Imaging methods are crucial in diagnosis:

  • contrast X-ray - typical enlargement of the duodenal window "C"
  • USG - identifies the tumor mass, enables FNAB
  • ERCP - imaging functions and pancreatic juice collection for cytology
  • CT
  • arteriography - important for determining tumor operability (infiltration of ports or mesenterics - almost this precludes radical performance)
  • oncomarkers - CEA, CA 19-9, CA 50
  • differential diagnosis(dif.dg) - benign tumors, pancreatic pseudocysts, chronic pancreatitis

Therapy

Therapy is optimally surgical:

  • Whipple surgery - in case of head injury - cephalic partial duodenopancreatectomy
  • cauda involvement - left resection of the pancreas
  • total duodenopancreatectomy, tube connection gastrojejunoanastomosis
  • palliative:
    • in bile duct oppression - biliary anastomoses (see above)
    • at imminent duodenal oppression - gastrojejunoanastomosis
  • postoperative measures - glycemic control , or iatrogenic DM therapy - this diabetes is very difficult to control due to the absence of glucagon! - great tendency to hypoglycemia !!!
  • pancreatic enzyme substitution
  • adjuvant - percutaneous conventional RT, it is not very sensitive to CHT, it is used only palliatively

Prognosis

  • very unfavorable, operational lethality is 5-15%
  • in early diagnosable cancer, 5-year survival is still only 3%



Links

Source